- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01867801
Portuguese Registry on Interventional Cardiology (PRIC)
Study Overview
Status
Conditions
Detailed Description
Cardiovascular disease remains the main cause of death in Portugal and approximately one quarter of these are directly to ischemic heart disease. In order to better characterize percutaneous coronary intervention in Portugal, the Portuguese Society of Cardiology has promoted the Portuguese registry on percutaneous coronary intervention.
This will include all adult patients (≥ 18 years), eligible for percutaneous coronary intervention (PCI) in accordance with PCI state-of-art recommendations (including unstable and stable coronary disease). The Cardiology department where the patient has been hospitalized is responsible for the patient inclusion in the study.
Excluded patients are those in whom the preferred treatment is Coronary Artery Bypass Graft (CABG), age under 18 years or life expectancy of less than 12 months.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
-
Coimbra, Portugal, 3000-306
- Recruiting
- CNCDC
-
Contact:
- Sandra M Corker
- Phone Number: 00351 239 838 101
- Email: sandra.corker@spc.pt
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
Patients with:
- stable angina or,
- stabilized angina pectoris or,
- atypical chest pain or,
- no chest pain but with documented silent ischemia
- At least one stenosis is present of at least 50% in one major native epicardial coronary artery and supplying viable myocardium
- Eligible for PCI
- Informed consent
Exclusion Criteria:
- Patients in whom the preferred treatment is CABG;
- Contra-indication to dual antiplatelet therapy
- Coronary artery disease precluding PCI
- A life expectancy of less than 1 year
- Age under 21
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Major adverse cardiac event rate (MACE) MACE: A composite of all cause death, documented Myocardial Infarction (MI), unplanned hospitalization leading to urgent revascularization.
Time Frame: 24 months
|
24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Total mortality
Time Frame: 12 month
|
Total mortality at 12 month
|
12 month
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Marco Costa, MD, Portuguese Society of Cardiology
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RNCI
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.